newsfilter
← Latest News
ACCESS Newswire·

Alzheimer's Phase 2 Trial in Agitation

  • IGC Pharma reported third quarter 2026 financial results & business updates as of November 9, 2026.
  • The CALMA Phase 2 trial for IGC-AD1 has completed enrollment with 170 randomized participants, exceeding the original target of 146.
  • Topline results for the CALMA trial are expected after the last participant receives the final dose, followed by AI data verification, database lock, unblinding, & independent statistical analysis.
  • The primary CALMA objective is to evaluate agitation in Alzheimer's patients at Week 6, with secondary analyses covering cognition, psychosis, sleep, caregiver burden, safety, & blood-based biomarkers.
  • On October 27, 2026, the Canadian Intellectual Property Office granted Canadian Patent No. 3,095,729 for IGC-AD1, bringing the total number of issued patents covering the therapy to five across the US, Canada, & Mexico.
  • IGC Pharma launched a private preview of the aha™ Agentic Harmonization Assistant on the AD Workbench to address data-integration challenges in neurological research.
  • The company introduced PRISM on October 13, an investigational application layer on the MINT-AD platform designed to link Alzheimer's risk insights to brain-health monitoring & engagement.
  • Q3 2026 revenue was approximately $328 thousand, representing a 72% increase from the prior year period.
  • R&D expenses decreased to approximately $1.0 million in Q3 2026 from $1.6 million in the prior year due to the completion of most CALMA site activations.
  • SG&A expenses decreased to approximately $979 thousand in Q3 2026 from $1.4 million in the prior year, reflecting lower depreciation & manufacturing costs following the 2025 sale of the Vancouver, Washington facility.
  • The company reported a net loss of approximately $2.046 million for the three months ended September 30, 2026.
  • As of September 30, 2026, the company held approximately $377 thousand in cash & cash equivalents.
  • During the nine months ended September 30, 2026, the company raised approximately $4.1 million in net proceeds from equity & debt financing.
  • The company maintains access to an undrawn $12 million revolving working capital credit facility with O-Bank Co., Ltd.
Company
IGC Pharma, Inc.
Keywords
Biotechnology, Earnings